175 related articles for article (PubMed ID: 28855212)
1. Sensitivity to
Lee E; Pain M; Wang H; Herman JA; Toledo CM; DeLuca JG; Yong RL; Paddison P; Zhu J
Cancer Res; 2017 Oct; 77(20):5518-5529. PubMed ID: 28855212
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells.
Ding Y; Hubert CG; Herman J; Corrin P; Toledo CM; Skutt-Kakaria K; Vazquez J; Basom R; Zhang B; Risler JK; Pollard SM; Nam DH; Delrow JJ; Zhu J; Lee J; DeLuca J; Olson JM; Paddison PJ
Cancer Discov; 2013 Feb; 3(2):198-211. PubMed ID: 23154965
[TBL] [Abstract][Full Text] [Related]
3. The FOXM1/BUB1B signaling pathway is essential for the tumorigenicity and radioresistance of glioblastoma.
Ma Q; Liu Y; Shang L; Yu J; Qu Q
Oncol Rep; 2017 Dec; 38(6):3367-3375. PubMed ID: 29039578
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
5. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Pezuk JA; Brassesco MS; Morales AG; de Oliveira JC; de Paula Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG
Cancer Gene Ther; 2013 Sep; 20(9):499-506. PubMed ID: 23887645
[TBL] [Abstract][Full Text] [Related]
7. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
8. A Large-Scale RNAi Screen Identifies SGK1 as a Key Survival Kinase for GBM Stem Cells.
Kulkarni S; Goel-Bhattacharya S; Sengupta S; Cochran BH
Mol Cancer Res; 2018 Jan; 16(1):103-114. PubMed ID: 28993509
[TBL] [Abstract][Full Text] [Related]
9. Modulation of miR-21 signaling by MPS1 in human glioblastoma.
Maachani UB; Tandle A; Shankavaram U; Kramp T; Camphausen K
Oncotarget; 2016 Aug; 7(33):52912-52927. PubMed ID: 25991676
[TBL] [Abstract][Full Text] [Related]
10. Etoposide-mediated glioblastoma cell death: dependent or independent on the expression of its target, topoisomerase II alpha?
Sevim H; Parkinson JF; McDonald KL
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1705-12. PubMed ID: 21904904
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
12. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
13. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages induce vasculogenic mimicry of glioblastoma multiforme through cyclooxygenase-2 activation.
Rong X; Huang B; Qiu S; Li X; He L; Peng Y
Oncotarget; 2016 Dec; 7(51):83976-83986. PubMed ID: 27824617
[TBL] [Abstract][Full Text] [Related]
15. Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.
Lerner RG; Grossauer S; Kadkhodaei B; Meyers I; Sidorov M; Koeck K; Hashizume R; Ozawa T; Phillips JJ; Berger MS; Nicolaides T; James CD; Petritsch CK
Cancer Res; 2015 Dec; 75(24):5355-66. PubMed ID: 26573800
[TBL] [Abstract][Full Text] [Related]
16. Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma.
Szczurek E; Misra N; Vingron M
Int J Cancer; 2013 Nov; 133(9):2123-32. PubMed ID: 23629686
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
[TBL] [Abstract][Full Text] [Related]
18. FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Chen C; Han G; Li Y; Yue Z; Wang L; Liu J
J Cell Biochem; 2019 Jan; 120(1):882-893. PubMed ID: 30216501
[TBL] [Abstract][Full Text] [Related]
19. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Chai Y; Wang C; Liu W; Fan Y; Zhang Y
J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
